Literature DB >> 22749745

A new technology for stabilization of biomolecules in tissues for combined histological and molecular analyses.

Christian Viertler1, Daniel Groelz, Sibylle Gündisch, Karl Kashofer, Bilge Reischauer, Peter H J Riegman, Rosa Winther, Ralf Wyrich, Karl-Friedrich Becker, Uwe Oelmüller, Kurt Zatloukal.   

Abstract

For accurate diagnosis, prediction of outcome, and selection of appropriate therapies, the molecular characterization of human diseases requires analysis of a broad spectrum of altered biomolecules, in addition to morphological features, in affected tissues such as tumors. In a high-throughput screening approach, we have developed the PAXgene Tissue System as a novel tissue stabilization technology. Comprehensive characterization of this technology in stabilized and paraffin-embedded human tissues and comparison with snap-frozen tissues revealed excellent preservation of morphology and antigenicity, as well as outstanding integrity of nucleic acids (genomic DNA, miRNA, and mRNA) and phosphoproteins. Importantly, PAXgene-fixed, paraffin-embedded tissues provided RNA quantity and quality not only significantly better than that obtained with neutral buffered formalin, but also similar to that from snap-frozen tissue, which currently represents the gold standard for molecular analyses. The PAXgene tissue stabilization system thus opens new opportunities in a variety of molecular diagnostic and research applications in which the collection of snap-frozen tissue is not feasible for medical, logistic, or ethical reasons. Furthermore, this technology allows performing histopathological analyses together with molecular studies in a single sample, which markedly facilitates direct correlation of morphological disease phenotypes with alterations of nucleic acids and other biomolecules.
Copyright © 2012 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22749745     DOI: 10.1016/j.jmoldx.2012.05.002

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  32 in total

1.  Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system.

Authors:  Sayaka Yuzawa; Hiroshi Nishihara; Shigeru Yamaguchi; Hiromi Mohri; Lei Wang; Taichi Kimura; Masumi Tsuda; Mishie Tanino; Hiroyuki Kobayashi; Shunsuke Terasaka; Kiyohiro Houkin; Norihiro Sato; Shinya Tanaka
Journal:  Mod Pathol       Date:  2016-04-22       Impact factor: 7.842

2.  Evaluation of colon cancer histomorphology: a comparison between formalin and PAXgene tissue fixation by an international ring trial.

Authors:  Sibylle Gündisch; Julia Slotta-Huspenina; Paolo Verderio; Chiara Maura Ciniselli; Sara Pizzamiglio; Christina Schott; Enken Drecoll; Christian Viertler; Kurt Zatloukal; Marcel Kap; Peter Riegman; Irene Esposito; Katja Specht; Gregor Babaryka; Martin Asslaber; Koppany Bodó; Michael den Bakker; Jan den Hollander; Falko Fend; Jens Neumann; Simone Reu; Aurel Perren; Rupert Langer; Alessandro Lugli; Ingrid Becker; Thomas Richter; Gian Kayser; Annette M May; Fatima Carneiro; José Manuel Lopes; Leslie Sobin; Heinz Höfler; Karl-Friedrich Becker
Journal:  Virchows Arch       Date:  2014-08-02       Impact factor: 4.064

3.  Cryopreservation of viable human lung tissue for versatile post-thaw analyses and culture.

Authors:  John E Baatz; Danforth A Newton; Ellen C Riemer; Chadrick E Denlinger; E Ellen Jones; Richard R Drake; Demetri D Spyropoulos
Journal:  In Vivo       Date:  2014 Jul-Aug       Impact factor: 2.155

4.  Molecular fixative enables expression microarray analysis of microdissected clinical cervical specimens.

Authors:  Gerald Li; Dirk van Niekerk; Dianne Miller; Thomas Ehlen; Cathie Garnis; Michele Follen; Martial Guillaud; Calum Macaulay
Journal:  Exp Mol Pathol       Date:  2014-01-08       Impact factor: 3.362

5.  Case-Control Study of Papillary Thyroid Carcinoma on Urinary and Dietary Iodine Status in South Korea.

Authors:  Joon-Hyop Lee; Ra-Yeong Song; Jin Wook Yi; Hyeong Won Yu; Hyungju Kwon; Su-Jin Kim; Young Jun Chai; June Young Choi; Jae Hoon Moon; Kyu Eun Lee; Young Joo Park; Sue K Park
Journal:  World J Surg       Date:  2018-05       Impact factor: 3.352

Review 6.  Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling.

Authors:  Mukesh Verma; Muin J Khoury; John P A Ioannidis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-14       Impact factor: 4.254

7.  Next-gen tissue: preservation of molecular and morphological fidelity in prostate tissue.

Authors:  Marc Gillard; Westin R Tom; Tatjana Antic; Gladell P Paner; Mark W Lingen; David J VanderWeele
Journal:  Am J Transl Res       Date:  2015-07-15       Impact factor: 4.060

8.  Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.

Authors:  Julia D Wulfkuhle; Daniela Berg; Claudia Wolff; Rupert Langer; Kai Tran; Julie Illi; Virginia Espina; Mariaelena Pierobon; Jianghong Deng; Angela DeMichele; Axel Walch; Holger Bronger; Ingrid Becker; Christine Waldhör; Heinz Höfler; Laura Esserman; Lance A Liotta; Karl-Friedrich Becker; Emanuel F Petricoin
Journal:  Clin Cancer Res       Date:  2012-10-08       Impact factor: 12.531

9.  Quantitation of fixative-induced morphologic and antigenic variation in mouse and human breast cancers.

Authors:  Robert D Cardiff; Neil E Hubbard; Jesse A Engelberg; Robert J Munn; Claramae H Miller; Judith E Walls; Jane Q Chen; Héctor A Velásquez-García; Jose J Galvez; Katie J Bell; Laurel A Beckett; Yue-Ju Li; Alexander D Borowsky
Journal:  Lab Invest       Date:  2013-02-11       Impact factor: 5.662

10.  Quantitative analysis of noncoding RNA from paired fresh and formalin-fixed paraffin-embedded brain tissues.

Authors:  Yehui Lv; Shiying Li; Zhihong Li; Ruiyang Tao; Yu Shao; Yijiu Chen
Journal:  Int J Legal Med       Date:  2019-12-01       Impact factor: 2.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.